Oncolytics Biotech has signed a clinical supply agreement with Coherus Oncology to study the combination of pelareorep, an oncolytic virus immunotherapy, with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, in patients with squamous cell anal carcinoma (SCAC) who have progressed after standard first-line chemotherapy and checkpoint inhibitors. The study, starting in early 2027 at a leading U.S. cancer center, aims to address the lack of approved second-line treatments for SCAC and explore the potential broader use of this combination in HPV-associated cancers. Pelareorep activates immune responses within tumors, potentially enhancing the effectiveness of PD-1 blockade by toripalimab. Positive results could pave the way for new therapies in difficult-to-treat HPV-related cancers.
Oncolytics Biotech's clinical supply agreement news comes with Pluang's Health sector data for context. Of 150 priced US Health stocks on Pluang, 50 rose and 100 fell today. ALNY traded at USD 164.62 with a 5.09% gain, AVAH was USD 11.63 down 4.98%, and WGS stood at USD 49.40 down 4.76%, as of Nov 14, 2026 00:01 WIB.
Susan R. Burns, Ph.D., President of the University of Mount Saint Vincent, has been awarded the 2027 Courageous Leadership Award for her visionary and bold leadership. Since 2021, she has led the university through significant transformation, includi...
Solo, a company specializing in privacy-preserving human verification, has integrated its SDK into JellyJelly, a social video app co-founded by Venmo's co-founder. This integration ensures that every JellyJelly account belongs to a real, unique perso...
The U.S. market for AI-enabled ophthalmic diagnostic devices is projected to grow from $72.5 million in 2026 to $267.2 million by 2033, expanding at a 20.5% CAGR. Growth is driven by rising diabetes-related eye diseases, FDA clearances for autonomous...
The global medical display monitors market, valued at $2.8 billion in 2025, is projected to grow to $4.0 billion by 2033 with a CAGR of 4.6%. Growth is fueled by rising adoption of digital imaging systems, demand for accurate diagnostics, and healthc...
Oppenheimer downgraded Enovix from Outperform to Perform as the company expands production in South Korea and shifts focus to drone and smart-eyewear customers. Enovix reported a 38% revenue increase to $11 million in Q3 but saw its adjusted loss wid...
